Risperidone in Children with Autism and Serious Behavioral Problems
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Atypical antipsychotic agents, which block postsynaptic dopamine and serotonin receptors, have advantages over traditional antipsychotic medications in the treatment of adults with schizophrenia and may be beneficial in children with autistic disorder who have serious behavioral disturbances. However, data on the safety and efficacy of atypical antipsychotic agents in children are limited. METHODS: We conducted a multisite, randomized, double-blind trial of risperidone as compared with placebo for the treatment of autistic disorder accompanied by severe tantrums, aggression, or self-injurious behavior in children 5 to 17 years old. The primary outcome measures were the score on the Irritability subscale of the Aberrant Behavior Checklist and the rating on the Clinical Global Impressions - Improvement (CGI-I) scale at eight weeks. RESULTS: A total of 101 children (82 boys and 19 girls; mean [+/-SD] age, 8.8+/-2.7 years) were randomly assigned to receive risperidone (49 children) or placebo (52). Treatment with risperidone for eight weeks (dose range, 0.5 to 3.5 mg per day) resulted in a 56.9 percent reduction in the Irritability score, as compared with a 14.1 percent decrease in the placebo group (P<0.001). The rate of a positive response, defined as at least a 25 percent decrease in the Irritability score and a rating of much improved or very much improved on the CGI-I scale, was 69 percent in the risperidone group (34 of 49 children had a positive response) and 12 percent in the placebo group (6 of 52, P<0.001). Risperidone therapy was associated with an average weight gain of 2.7+/-2.9 kg, as compared with 0.8+/-2.2 kg with placebo (P<0.001). Increased appetite, fatigue, drowsiness, dizziness, and drooling were more common in the risperidone group than in the placebo group (P<0.05 for each comparison). In two thirds of the children with a positive response to risperidone at eight weeks (23 of 34), the benefit was maintained at six months. CONCLUSIONS: Risperidone was effective and well tolerated for the treatment of tantrums, aggression, or self-injurious behavior in children with autistic disorder. The short period of this trial limits inferences about adverse effects such as tardive dyskinesia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Methylphenidate, atomoxetine and guanfacine are beneficial for ADHD symptoms in ASD (Table 2 204 -206 )”
From Autism spectrum disorder (2020) · cites this paper as [206]
In the citing paper
“Currently, only two drugs have been approved by the United States (U.S.) Food and Drug Administration (FDA) for use in the ASD population: risperidone [23] and aripiprazole [24]. Both drugs are approved for the treatment of irritability in children and adolescents with ASD.”
From Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms (2025) · cites this paper as [23]
In the citing paper
“as the two drugs that have received FDA approval for use in ASD, risperidone, and aripiprazole, are both for the indication of “irritability” [23, 24]”
From Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms (2025) · cites this paper as [23]
In the citing paper
“risperidone and aripiprazole, which are both FDA-approved for irritability in children and adolescents with ASD [23, 24].”
From Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms (2025) · cites this paper as [23]
In the citing paper
“and significant improvement in core autism symptoms [601-604].”
From Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings (2012) · cites this paper as [601]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Littell, R. C. (1996) · Medical Entomology and Zoology · Cited by 10,547
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
SIMPSON, G. M., B., M., B., G., ANGUS, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,264
ECDEU Assessment Manual: (591322011-001)
Guy, W. (1976) · PsycEXTRA Dataset · doi:10.1037/e591322011-001 · Cited by 1,896
Kapur, S., & Seeman, P. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.3.360 · Cited by 1,140
Pervasive Developmental Disorders in preschool children
Chakrabarti, S. (2001) · JAMA · doi:10.1001/jama.285.24.3093 · Cited by 1,132
Gibbons, R. D. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820210073009 · Cited by 719
McDougle, C. J., Holmes, J. P., Carlson, D. C., Pelton, G. H., Cohen, D. J., & Price, L. H. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.7.633 · Cited by 427
Self-citationDiagnosing Autism: Analyses of Data from the Autism Diagnostic Interview
Lord, C., Pickles, A., McLennan, J., Rutter, M., Bregman, J., Folstein, S., Fombonne, E., Leboyer, M., & Minshew, N. (1997) · Journal of Autism and Developmental Disorders · doi:10.1023/a:1025873925661 · Cited by 373
The Vineland Adaptive Behavior Scales: Supplementary Norms for Individuals with Autism
Carter, A. S., Volkmar, F. R., Sparrow, S. S., Wang, J.-J., Lord, C., Dawson, G., Fombonne, E., Loveland, K., Mesibov, G., & Schopler, E. (1998) · Journal of Autism and Developmental Disorders · doi:10.1023/a:1026056518470 · Cited by 367
Self-citation
Cited by
Items 401–500 of 1,000
The autism inpatient collection: methods and preliminary sample description
(ADDIRC), F. T. A. A. D. D. I. R. C., Siegel, M., Smith, K. A., Mazefsky, C., Gabriels, R. L., Erickson, C., Kaplan, D., Morrow, E. M., Wink, L., & Santangelo, S. L. (2015) · Molecular Autism · doi:10.1186/s13229-015-0054-8 · Cited by 60
Hara, Y., Ago, Y., Taruta, A., Katashiba, K., Hasebe, S., Takano, E., Onaka, Y., Hashimoto, H., Matsuda, T., & Takuma, K. (2016) · Autism Research · doi:10.1002/aur.1596 · Cited by 59
“Clinical studies show that the atypical antipsychotic drugs risperidone [McCracken et al., 2002; Shea et al., 2004] and aripiprazole [Marcus et al., 2009; Owen et al., 2009], and the ADHD drugs methylphenidate [Posey et al., 2007] and atomoxetine [Harfterkamp e al., 2012] improve abnormal behaviors…”
BackgroundSmith, T. H. (2012) · The Behavior Analyst · doi:10.1007/bf03392269 · Cited by 75
Strategies for pharmacologic treatment of high functioning autism and Asperger syndrome
Towbin, K. E. (2003) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/s1056-4993(02)00049-4 · Cited by 60
Autism and Familial Major Mood Disorder: Are They Related?
DeLong, R. (2004) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.16.2.199 · Cited by 62
Scott, L. J., & Dhillon, S. (2007) · Pediatric Drugs · doi:10.2165/00148581-200709050-00006 · Cited by 228
Fleischhaker, C., Heiser, P., Hennighausen, K., Herpertz‐Dahlmann, B., Holtkamp, K., Mehler‐Wex, C., Rauh, R., Remschmidt, H., Schulz, E., & Warnke, A. (2008) · Journal of Neural Transmission · doi:10.1007/s00702-008-0105-9 · Cited by 62
Wheeler, A., Raspa, M., Bann, C., Bishop, E. E., Hessl, D. R., Sacco, P., & Bailey, D. B. (2013) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.36232 · Cited by 74
“This decrease in challenging externalizing behaviors in the older age groups is also in contrast to studies of individuals with autism and other developmental disabilities, where these behaviors have been noted to be chronic and stable across age [Murphy et al., 2009; Matson et al., 2010].”
ResultManning‐Courtney, P., Murray, D. S., Currans, K., Johnson, H., Bing, N. M., Kroeger-Geoppinger, K., Sorensen, R., Bass, J., Reinhold, J., Johnson, A. J., et al. (2012) · Emerald Group Publishing Limited eBooks · doi:10.1016/j.cppeds.2012.08.001 · Cited by 91
Arnold, L. E., Farmer, C., Kraemer, H. C., Davies, M., Witwer, A., Chuang, S., DiSilvestro, R., McDougle, C. J., McCracken, J., Vitiello, B., et al. (2010) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2009.0022 · Cited by 58
Self-citationKENT, J. M., Hough, D. W., Singh, J. B., Karcher, K., & Pandina, G. (2013) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2012.0058 · Cited by 62
Masi, G., Cosenza, A., Millepiedi, S., Muratori, F., Pari, C., & Salvadori, F. (2009) · CNS Drugs · doi:10.2165/00023210-200923060-00005 · Cited by 61
Lamy, M., & Erickson, C. A. (2018) · Current problems in pediatric and adolescent health care · doi:10.1016/j.cppeds.2018.08.015 · Cited by 69
Alfageh, B. H., Wang, Z., Mongkhon, P., Besag, F., Alhawassi, T. M., Brauer, R., & Wong, I. C. K. (2019) · Pediatric Drugs · doi:10.1007/s40272-019-00333-x · Cited by 68
Oliver, P., Huline‐Dickens, S., Ahmed, M. Z., Bouras, N., Cooray, S., Deb, S. S., Knapp, M. R. J., Hare, M., Meade, M., Reece, B., et al. (2009) · Journal of Intellectual Disability Research · doi:10.1111/j.1365-2788.2009.01195.x · Cited by 58
Research in child and adolescent psychopharmacology: recent accomplishments and new challenges
Vitiello, B. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0414-3 · Cited by 66
Self-citationAutism and pervasive developmental disorders
Gadia, C. A., Tuchman, R., & Rotta, N. T. (2004) · Jornal de Pediatria · doi:10.2223/1172 · Cited by 55
Nijmeijer, J. S., Hartman, C. A., Rommelse, N. N. J., Altink, M. E., Buschgens, C. J. M., Fliers, E. A., Franke, B., Minderaa, R. B., Ormel, J., Sergeant, J. A., et al. (2010) · Journal of Child Psychology and Psychiatry · doi:10.1111/j.1469-7610.2010.02277.x · Cited by 57
“…candidate gene for ASD, as inefficient PFC functioning is also implicated in ASD (e.g. Geurts et al., 2004), and dopamine antagonists, such as risperidone, improve some aspects of autism, such as irritability (e.g., McCracken et al., 2002) and executive functioning (Troost et al., 2006).”
BackgroundCharacteristics of Children Prescribed Antipsychotics: Analysis of Routinely Collected Data
Brophy, S. T., Kennedy, J. I., Fernández‐Gutiérrez, F., John, A. M., Potter, R., Linehan, C., & Kerr, M. (2018) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2017.0003 · Cited by 60
“…higher levels of adverse events such as somnolence, upper respiratory infection (Pandina et al. 2007), and higher weight gain (Scahill et al. 2016; McCracken et al. 2002) Therefore, the evidence base for behavioral management using antipsychotics is still at an early stage and there are few…”
de León, J., Sandson, N. B., & Cozza, K. L. (2008) · Psychosomatics · doi:10.1176/appi.psy.49.3.258 · Cited by 63
Roke, Y., Buitelaar, J. K., Boot, A. M., Tenback, D. E., & van Harten, P. N. (2012) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2011.0109 · Cited by 62
Tardive dyskinesia and withdrawal emergent syndrome in children
Mejia, N. I., & Jankovic, J. J. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.58 · Cited by 60
Use of psychotropic medications in Italian children and adolescents
Clavenna, A., Rossi, E., DeRosa, M., & Bonati, M. R. (2006) · European Journal of Pediatrics · doi:10.1007/s00431-006-0244-7 · Cited by 63
Häßler, F., & Reis, O. (2010) · Developmental Disabilities Research Reviews · doi:10.1002/ddrr.119 · Cited by 58
Genetics of Common Antipsychotic-Induced Adverse Effects
MacNeil, R. R., & Müller, D. J. (2016) · Complex Psychiatry · doi:10.1159/000445802 · Cited by 67
Hara, Y., Ago, Y., Taruta, A., Hasebe, S., Kawase, H., Tanabe, W., Tsukada, S., Nakazawa, T., Hashimoto, H., Matsuda, T., et al. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4703-9 · Cited by 60
Johnson, C. R., Barto, L., Worley, S., Rothstein, R., & Alder, M. L. (2023) · Sleep Medicine · doi:10.1016/j.sleep.2023.08.033 · Cited by 58
Iffland, M., Livingstone, N., Jorgensen, M. L., Hazell, P., & Gillies, D. M. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011769.pub2 · Cited by 71
Retrospective Study of Quetiapine in Children and Adolescents with Pervasive Developmental Disorders
Hardan, A. Y., Jou, R. J., & Handen, B. L. (2005) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-005-3306-1 · Cited by 55
Weight Gain Effects of Second-Generation Antipsychotic Treatment in Autism Spectrum Disorder
Yoon, Y., Wink, L. K., Pedapati, E. V., Horn, P. S., & Erickson, C. A. (2016) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2016.0049 · Cited by 57
“…and aripiprazole are both approved by the U.S. Food and Drug Association for treatment of ASD-associated irritability based on several large randomized controlled trials, which demonstrated the efficacy and safety of these medications (McCracken et al. 2002; Marcus et al.2009; Owen et al. 2009).”
Tyrer, P. J., Oliver, P., Romeo, R., Knapp, M. R. J., Huline‐Dickens, S., Bouras, N., Ahmed, M. Z., Cooray, S., Deb, S. S., Murphy, D., et al. (2009) · Health Technology Assessment · doi:10.3310/hta13210 · Cited by 56
On Behalf of the ISACA Guideline Working Group, D’Alò, G. L., De Crescenzo, F., Amato, L., Cruciani, F., Davoli, M., Fulceri, F., Minozzi, S., Mitrova, Z., Morgano, G. P., et al. (2021) · Health and Quality of Life Outcomes · doi:10.1186/s12955-021-01669-0 · Cited by 54
Moreno, C., Merchán‐Naranjo, J., Álvarez, M., Baeza, I., Alda, J. A., Martínez‐Cantarero, C., Parellada, M., Sánchez, B., De La Serna, E., Giráldez, M., et al. (2010) · Bipolar Disorders · doi:10.1111/j.1399-5618.2010.00797.x · Cited by 54
Clinic-Based Retrospective Analysis of Psychopharmacology for Behavior in Fragile X Syndrome
Berry-Kravis, E., Sumis, A., Hervey, C., & Mathur, S. (2012) · International Journal of Pediatrics · doi:10.1155/2012/843016 · Cited by 54
“This is consistent with the finding that risperidone is safe and effective for aggressive and aberrant behaviors in a double-blind placebocontrolled trial in individuals with autism [33].”
ResultExamining the Clinical Correlates of Autism Spectrum Disorder in Youth by Ascertainment Source
Joshi, G., Faraone, S. V., Wozniak, J., Petty, C., Fried, R., Galdo, M., Furtak, S. L., McDermott, K., Epstien, C., Walker, R., et al. (2014) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-014-2063-4 · Cited by 51
Janowsky, D. S., Shetty, M., Barnhill, J., Elamir, B., & Davis, J. M. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s146114570400481x · Cited by 54
The psychopharmacology of autism spectrum disorder and Rett syndrome
Persico, A. M., Ricciardello, A., & Cucinotta, F. (2019) · Handbook of clinical neurology · doi:10.1016/b978-0-444-64012-3.00024-1 · Cited by 60
A Neurodevelopment Approach for a Transitional Model of Early Onset Schizophrenia
Berardis, D. D., Filippis, S. D., Masi, G., Vicari, S., & Zuddas, A. (2021) · Brain Sciences · doi:10.3390/brainsci11020275 · Cited by 63
“4 on language and social withdrawal [96]; in schizophrenia, effect size for risperidone is 0.”
BackgroundJoshi, G., Wozniak, J. R., Fitzgerald, M., Faraone, S. V., Fried, R. S., Galdo, M., Furtak, S. L., Conroy, K., Kilcullen, J. R., Belser, A. H., et al. (2018) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-018-3542-9 · Cited by 62
“Psychiatric referrals of children with ASD are frequently driven by emotional and behavioral symptoms that often include irritability/aggression (McCracken et al. 2002; RUPP 2005), anxiety (Gadow et al.”
BackgroundYoo, J. H., Valdovinos, M. G., & Williams, D. C. (2007) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-006-0322-8 · Cited by 56
Galantamine in the Treatment of Adult Autism: A Report of Three Clinical Cases
Hertzman, M. (2003) · The International Journal of Psychiatry in Medicine · doi:10.2190/je5q-1nft-fl40-7pmw · Cited by 53
Lindsay, R. L., Eugene Arnold, L., Aman, M. G., Vitiello, B., Posey, D. J., McDougle, C. J., Scahill, L., Pachler, M., McCracken, J. T., Tierney, E., et al. (2006) · Journal of Intellectual & Developmental Disability · doi:10.1080/13668250601006924 · Cited by 52
Self-citationPsychotropic drug efficacy and side effects for persons with autism spectrum disorders
Matson, J. L., & Hess, J. A. (2010) · Research in Autism · doi:10.1016/j.rasd.2010.04.004 · Cited by 59
“All rights reserved. doi:10.1016/j.rasd.2010.04.004 to treatment targets as challenging behaviors, as opposed to irritability in other studies (McCracken et al., 2002; Scott & Dhillon, 2007).”
ResultInfluentialSwim stress exaggerates the hyperactive mesocortical dopamine system in a rodent model of autism
Nakasato, A., Nakatani, Y., Seki, Y., Tsujino, N., Umino, M., & Arita, H. (2007) · Brain Research · doi:10.1016/j.brainres.2007.11.043 · Cited by 54
“For example, research units on pediatric psychopharmacology autism network (McCracken et al., 2002) have reported that risperidone, which blocks postsynaptic dopamine and serotonin receptors, is effective for the treatment of tantrums, aggression, or selfinjurious behavior in children with autism.”
Malone, R. P., & Waheed, A. (2009) · Drugs · doi:10.2165/00003495-200969050-00003 · Cited by 53
Vieweg, W. V. R., Sood, A. B., Pandurangi, A. K., & Silverman, J. J. (2005) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2004.00444.x · Cited by 56
Manter, M. A., Birtwell, K. B., Bath, J., Friedman, N. D. B., Keary, C. J., Neumeyer, A. M., Palumbo, M. L., Thom, R. P., Stonestreet, E., Brooks, H., et al. (2025) · BMC Medicine · doi:10.1186/s12916-024-03814-0 · Cited by 51
“Currently, only two drugs have been approved by the United States (U.S.) Food and Drug Administration (FDA) for use in the ASD population: risperidone [23] and aripiprazole [24].”
InfluentialSelf-citationBennett (2023) · doi:10.1097/yco.0000000000000775 · Cited by 51
Lamberti, M., Siracusano, R., Italiano, D., Alosi, N., Cucinotta, F., Rosa, G. D., Germanò, E., Spina, E., & Gagliano, A. (2016) · Pediatric Drugs · doi:10.1007/s40272-016-0183-3 · Cited by 56
An Update on Medication Management of Behavioral Disorders in Autism
Baribeau, D. A., & Anagnostou, E. A. (2014) · Current Psychiatry Reports · doi:10.1007/s11920-014-0437-0 · Cited by 62
Khalaj, M., Saghazadeh, A., Shirazi, E., Shalbafan, M., Alavi, K., Shooshtari, M. H., Laksari, F. Y., Hosseini, M. A., Mohammadi, M.-R., & Akhondzadeh, S. (2018) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2018.04.022 · Cited by 57
Ellul, P., Delorme, R., & Cortese, S. (2018) · CNS Drugs · doi:10.1007/s40263-018-0571-z · Cited by 53
Vieweg, W. V. R., Julius, D. A., Fernandez, A., Tassone, D. M., Narla, S. N., & Pandurangi, A. K. (2006) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v08n0104 · Cited by 51
Hoekstra, P. J., Troost, P. W., Lahuis, B. E., Mulder, H., Mulder, E. J., Franke, B., Buitelaar, J. K., Anderson, G. M., Scahill, L., & Minderaa, R. B. (2010) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2009.0071 · Cited by 51
Self-citationFido, A. A., & Al-Saad, S. (2008) · Medical Principles and Practice · doi:10.1159/000141508 · Cited by 56
Evaluation and Management of Language and Speech Disorders in Preschool Children
Feldman, H. M. (2005) · Pediatrics in Review · doi:10.1542/pir.26-4-131 · Cited by 56
Use of Atypical Antipsychotics in the Treatment of Autistic Disorder
Stachnik, J. M., & Nunn-Thompson, C. (2007) · Annals of Pharmacotherapy · doi:10.1345/aph.1h527 · Cited by 51
Monoamines, GABA, Glutamate, and Aggression
Miczek, K. A., & Fish, E. W. (2005) · Biology of Aggression · doi:10.1093/acprof:oso/9780195168761.003.0005 · Cited by 46
Matson, J. L., & Dempsey, T. (2009) · Research in Developmental Disabilities · doi:10.1016/j.ridd.2008.10.001 · Cited by 43
Health-related quality of life for children with ASD: Associations with behavioral characteristics
Kuhlthau, K. A., Kovacs, E. A., Hall, T. A., Clemmons, T., Orlich, F., Delahaye, J., & Sikora, D. M. (2013) · Research in Autism · doi:10.1016/j.rasd.2013.04.006 · Cited by 56
Autism: A review for family physicians
Karande, S. (2006) · Indian Journal of Medical Sciences · doi:10.4103/0019-5359.25683 · Cited by 60
Joshi, G., Wozniak, J., Faraone, S. V., Fried, R., Chan, J., Furtak, S., Grimsley, E., Conroy, K., Kilcullen, J. R., Woodworth, K. Y., et al. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000499 · Cited by 48
“Although there are drugs to treat irritability and hyperactivity in ASD, to date, no medications have been shown to reliably improve core features of the disorder.(5,6) Emerging evidence on the safety and efficacy of glutamatergic agents for the treatment of social deficits in ASD is encouraging.”
BackgroundNovel treatments for autism spectrum disorder based on genomics and systems biology
Baribeau, D. A., & Anagnostou, E. A. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107939 · Cited by 55
The Development of the Mesoprefrontal Dopaminergic System in Health and Disease
Islam, K. U. S., Meli, N., & Blaess, S. (2021) · Frontiers in Neural Circuits · doi:10.3389/fncir.2021.746582 · Cited by 58
Intervention for autistic spectrum disorders
Filipek, P. A., Steinberg-Epstein, R., & Book, T. M. (2006) · NeuroRx · doi:10.1016/j.nurx.2006.01.014 · Cited by 61
Trends in Psychotropic Medication Costs for Children and Adolescents, 1997-2000
Martin, A., & LESLIE, D. L. (2003) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/archpedi.157.10.997 · Cited by 50
Self-citationCapone, G. T., Goyal, P., Grados, M., Smith, B., & Kammann, H. (2008) · Journal of Developmental & Behavioral Pediatrics · doi:10.1097/dbp.0b013e318165c100 · Cited by 49
Self-citationHollander, E., Friedberg, J. P., Wasserman, S., Yeh, C.-C., & Iyengar, R. L. (2006) · Springer eBooks · doi:10.1007/0-387-23370-9_5 · Cited by 58
Pistollato, F., Forbes-Hernández, T. Y., Iglesias, R. C., Ruíz, R., Elexpuru-Zabaleta, M., Cianciosi, D., Giampieri, F., & Battino, M. A. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104579 · Cited by 52
Evidence-Based Treatments for Autism Spectrum Disorder
Politte, L. C., Howe, Y. J., Nowinski, L. A., Palumbo, M., & McDougle, C. J. (2015) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-015-0031-z · Cited by 57
Self-citationSiegel, M. S., Milligan, B., Chemelski, B. E., Payne, D., Ellsworth, B., Harmon, J., Teer, O., & Smith, K. A. (2014) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-014-2157-z · Cited by 50
Chmielewski, W. X., & Beste, C. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2014.11.002 · Cited by 55
Determination of risperidone and enantiomers of 9-hydroxyrisperidone in plasma by LC-MS/MS
Cabovska, B., Cox, S., & Vinks, A. A. T. M. M. (2007) · Journal of Chromatography B · doi:10.1016/j.jchromb.2007.02.007 · Cited by 48
Pharmacotherapy of Aggression in Child and Adolescent Psychiatric Disorders
Gurnani, T., Ivanov, I., & Newcorn, J. H. (2016) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2015.0167 · Cited by 51
“…placebo-controlled RCTs with risperidone were conducted in children with autism and DBD, in which significant improvements in irritability were observed on the Aberrant Behavior Checklist (ABC)–Irritability subscale after an 8 week treat-ment period (McCracken et al. 2002; Shea et al. 2004).”
Prevalence of Atypical Antipsychotic Drug Use Among Commercially Insured Youths in the United States
Curtis, L. H., Masselink, L. E., Østbye, T., Hutchison, S., Dans, P. E., Wright, A., Krishnan, R. R., & Schulman, K. A. (2005) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/archpedi.159.4.362 · Cited by 51
“Third, data regarding safety and efficacy of atypical antipsychotics in pediatric populations are limited.(23,25) Finally, preliminary evidence suggests that even moderate doses of risperidone and olanzapine may be associated with weight gain, sedation, and extrapyramidal adverse effects that are more prevalent and mo…”
BackgroundAutism Spectrum Disorders: Pharmacotherapy for Challenging Behaviors
Matson, J. L., & Dempsey, T. (2007) · Journal of Developmental and Physical Disabilities · doi:10.1007/s10882-007-9088-y · Cited by 49
Using antipsychotics for behavioral problems in children
Shafiq, S., & Pringsheim, T. M. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1509069 · Cited by 57
“Risperidone was associated with somnolence and sedation in 72.5% compared to 7.7% of the placebo group in Shea et al. and 49.0% vs. 12.0% in RUPP 2002.”
ResultInfluentialAntipsychotic Treatment Among Youths With Attention-Deficit/Hyperactivity Disorder
Sultan, R. S., Wang, S., Crystal, S., & Olfson, M. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.7850 · Cited by 49
Bergmann, T. J., Sappok, T., Diefenbacher, A., Dames, S., Heinrich, M., Ziegler, M. D., & Dziobek, I. (2015) · Research in Developmental Disabilities · doi:10.1016/j.ridd.2015.05.011 · Cited by 54
the Research Units on Pediatric Psychopharmacology (RUPP) Autism Network), Scahill, L., Hallett, V., Aman, M. G., McDougle, C. J., Eugene Arnold, L., McCracken, J. T., Tierney, E., Deng, Y., Dziura, J., et al. (2013) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-012-1689-3 · Cited by 47
Self-citationLi, Y., Wang, T., Wan, Q., Wang, Q., Chen, Z., Gao, Y., Ye, Y., Lin, J., Zhao, B., Wang, H., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-3882 · Cited by 50
Emerging drugs for the treatment of irritability associated with autism spectrum disorder
Shamabadi, A., Karimi, H., Bahri, R. A., Motavaselian, M., & Akhondzadeh, S. (2024) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2024.2313650 · Cited by 50
“Risperidone is an atypical anti-psychotic whose short-term and long-term effects on the irritability of patients with ASD were shown in previous placebo-controlled clinical studies [9,10].”
BackgroundBeyond the Roadblocks: Transitioning to Adulthood With Asperger's Disorder
Lawrence, D. H., Alleckson, D. A., & Bjorklund, P. (2009) · Archives of Psychiatric Nursing · doi:10.1016/j.apnu.2009.07.004 · Cited by 51
Aripiprazole for the treatment of irritability associated with autism
Farmer, C., & Aman, M. G. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.557661 · Cited by 50
“On the face of it, aripiprazole does not have quite the positive clinical impact on average that was reported for risperidone by the Research Units on Pediatric Psychopharmacology Autism Network [28].”
Self-citationUnanswered Questions Regarding Atypical Antipsychotic Use in Aggressive Children and Adolescents
Patel, N. C., Crismon, M. L., Hoagwood, K., & Jensen, P. S. (2005) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2005.15.270 · Cited by 47
“…aggression originate from controlled trials evaluating different patient populations (Aman et al. 2002; Buitelaar et al. 2001; Findling et al. 2000; McCracken et al. 2002; Snyder et al. 2002; for aggression originate from patients of sub-average intelligence or with developmental disorders (Aman…”
InfluentialWhite, S. W., Kreiser, N. L., Pugliese, C., & Scarpa, A. (2012) · Autism · doi:10.1177/1362361311431951 · Cited by 44
Gabriels, R. L., Pan, Z., Guérin, N. A., Dechant, B., & Mesibov, G. B. (2018) · Frontiers in Veterinary Science · doi:10.3389/fvets.2018.00156 · Cited by 55
Investigating mental health crisis in youth with autism spectrum disorder
Vasa, R. A., Hagopian, L. P., & Kalb, L. G. (2019) · Autism Research · doi:10.1002/aur.2224 · Cited by 55
“Mental health crises can lead to restrictive placement, police involvement, and significant caregiver stress [McNellis & Harris, 2014; Tint, Palucka, Bradley, Weiss, & Lunsky, 2017; Weiss & Lunsky, 2011].”
BackgroundCohen, I. L., Yoo, J. H., Goodwin, M. S., & Moskowitz, L. J. (2011) · Springer eBooks · doi:10.1007/978-1-4419-8065-6_15 · Cited by 57
Assessing Childhood Psychopathology and Developmental Disabilities
Matson, J. L., Andrasik, F., & Matson, M. L. (2008) · Springer eBooks · doi:10.1007/978-0-387-09528-8 · Cited by 50
van Schaick, E. A., Lechat, P. P., Remmerie, B. M. M., Ko, G. N., Lasseter, K. C., & Mannaert, E. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80163-7 · Cited by 45
Diagnosis and treatment of autism spectrum disorders
Manning‐Courtney, P., Brown, J., Molloy, C. A., Reinhold, J., Murray, D. S., Sorensen-Burnworth, R., Messerschmidt, T., & Kent, B. (2003) · Current problems in pediatric and adolescent health care · doi:10.1016/s1538-5442(03)00108-1 · Cited by 62
Neurochemistry and Molecular Neurobiology of Aggressive Behavior
Miczek, K. A., Faccidomo, S., Fish, E. W., & DeBold, J. F. (2006) · Springer eBooks · doi:10.1007/978-0-387-30405-2_7 · Cited by 50
Varley, C. K., & McClellan, J. (2009) · JAMA · doi:10.1001/jama.2009.1558 · Cited by 45
Pharmacotherapy in autism spectrum disorders, including promising older drugs warranting trials
Hellings, J. A. (2023) · World Journal of Psychiatry · doi:10.5498/wjp.v13.i6.262 · Cited by 52
Lemmon, M. E., Gregas, M., & Jeste, S. S. (2011) · Journal of Child Neurology · doi:10.1177/0883073810382143 · Cited by 45
Uçar, S. K., Özbaran, B., Demiral, N., Yüncü, Z., Erermiş, S., & Çöker, M. (2009) · Brain and Development · doi:10.1016/j.braindev.2008.12.010 · Cited by 44
Vohra, R., Madhavan, S., Sambamoorthi, U., StPeter, C., Poe, S. G., Dwibedi, N., & Ajmera, M. (2016) · Drugs - Real World Outcomes · doi:10.1007/s40801-016-0096-z · Cited by 62
“It is well known that risperidone therapy is associated with adverse events such as sedation, obesity, tardive dyskinesia, and side effects such as increased appetite, fatigue, drowsiness, dizziness, and drooling [20, 27].”
BackgroundLecavalier, L., Smith, T., Johnson, C., Bearss, K., Swiezy, N., Aman, M. G., Sukhodolsky, D. G., Deng, Y., Dziura, J., & Scahill, L. (2017) · Journal of Abnormal Child Psychology · doi:10.1007/s10802-016-0233-x · Cited by 44
Self-citationLee, B., Lee, J., Cheon, J.-H., Sung, H.-K., Cho, S., & Chang, G. T. (2018) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2018/1057539 · Cited by 40
Metadata
- Authors
- McCracken, J. T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., Arnold, L. E., Lindsay, R., Nash, P., Hollway, J., McDougle, C. J., Posey, D., Swiezy, N., Kohn, A., Scahill, L., Martin, A., Koenig, K., Volkmar, F., Carroll, D., Lancor, A., Tierney, E., Ghuman, J., Gonzalez, N. M., Grados, M., Vitiello, B., Ritz, L., Davies, M., Robinson, J., & McMahon, D.
- Affiliations
- University of California, Los Angeles (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2002-08
- Volume
- 347
- Issue
- 5
- Pages
- 314-321
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1968430210
- Cited by
- 1,574
- References
- 25
- Citations by year
- 2026: 50 · 2025: 68 · 2024: 54 · 2023: 43 · 2022: 51 · 2021: 77 · 2020: 54 · 2019: 43 · 2018: 69 · 2017: 56 · 2016: 57 · 2015: 59 · 2014: 57 · 2013: 88 · 2012: 88
- FWCI
- 30.55
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Funders
- National Institutes of Health (n01mh070009-000, n01mh070001-008, n01mh070010-001, n01mh080011-005)
- National Institute of Mental Health (N01-MH-80011, N01 MH 70010, K23MH001883, N01 MH-70001, N01 MH 70009)
- National Center for Research Resources (M01-RR 00750, M01 RR-00052, M01-RR-00034, M01RR000750, M01RR000052, M01RR000034)
- Topics
- Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Psychology › Developmental and Educational Psychology › Behavioral and Psychological Studies
- Keywords
- risperidone, autism spectrum disorder, atypical antipsychotics, irritability, tantrums, aggression, self-harm, Aberrant Behavior Checklist, weight gain, adverse effects, children
- MeSH terms
- Adolescent, Autistic Disorder, Child, Child Behavior, Child, Preschool, Double-Blind Method, Female, Humans, Male, Antipsychotic Agents, Treatment Outcome, Risperidone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.